Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 3
1998 1
1999 3
2000 3
2002 3
2003 2
2004 3
2005 6
2006 1
2007 2
2008 1
2009 2
2010 2
2011 1
2012 1
2014 1
2015 3
2016 7
2017 4
2018 6
2019 6
2020 7
2021 11
2022 6
2023 6
2024 5
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A.
Mouri A, Kisohara A, Morita R, Ko R, Nakagawa T, Makiguchi T, Isobe K, Ishikawa N, Kondo T, Akiyama M, Bessho A, Honda R, Yoshimura K, Kagamu H, Kato S, Kobayashi K, Kaira K, Maemondo M. Mouri A, et al. Among authors: bessho a. ESMO Open. 2024 Oct;9(10):103939. doi: 10.1016/j.esmoop.2024.103939. Epub 2024 Oct 11. ESMO Open. 2024. PMID: 39395258 Free PMC article. Clinical Trial.
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.
Kanda S, Niho S, Kurata T, Nomura S, Kawashima Y, Iwama E, Yokoyama T, Watanabe Y, Tanaka H, Fujiwara Y, Zenke Y, Azuma K, Taniguchi H, Toyozawa R, Hosomi Y, Murakami H, Hara S, Bessho A, Yamamoto N, Ohe Y. Kanda S, et al. Among authors: bessho a. Clin Cancer Res. 2025 Jun 13;31(12):2317-2326. doi: 10.1158/1078-0432.CCR-24-3532. Clin Cancer Res. 2025. PMID: 40162917 Free PMC article. Clinical Trial.
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.
Hotta K, Saeki S, Sakata S, Yamaguchi M, Harada D, Bessho A, Tanaka K, Inoue K, Inoue K, Gemba K, Kubo T, Sato A, Ichihara E, Watanabe H, Kishimoto J, Shioyama Y, Katsui K, Sugio K, Kiura K. Hotta K, et al. Among authors: bessho a. Int J Clin Oncol. 2025 Mar;30(3):497-503. doi: 10.1007/s10147-025-02696-3. Epub 2025 Feb 5. Int J Clin Oncol. 2025. PMID: 39910007 Free PMC article. Clinical Trial.
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50.
Kogure Y, Hashimoto H, Daga H, Fukuda Y, Bessho A, Yamada T, Toi Y, Kimura T, Yoshioka H, Azuma K, Furuya N, Fukui Y, Saito AM, Yamamoto N, Saka H, Kondo M. Kogure Y, et al. Among authors: bessho a. JTO Clin Res Rep. 2024 Dec 24;6(3):100784. doi: 10.1016/j.jtocrr.2024.100784. eCollection 2025 Mar. JTO Clin Res Rep. 2024. PMID: 40007549 Free PMC article.
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
Taniguchi Y, Shimokawa T, Takiguchi Y, Misumi T, Nakamura Y, Kawashima Y, Furuya N, Shiraishi Y, Harada T, Tanaka H, Miura S, Uchiyama A, Nakahara Y, Tokito T, Naoki K, Bessho A, Goto Y, Seike M, Okamoto H. Taniguchi Y, et al. Among authors: bessho a. Clin Cancer Res. 2022 Oct 14;28(20):4402-4409. doi: 10.1158/1078-0432.CCR-22-1687. Clin Cancer Res. 2022. PMID: 35980349 Free PMC article. Clinical Trial.
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K, Ozawa Y, Hara S, Tanizaki J, Azuma K, Omori S, Tachihara M, Nishino K, Bessho A, Chiba Y, Haratani K, Sakai K, Nishio K, Yamamoto N, Nakagawa K. Hayashi H, et al. Among authors: bessho a. Clin Cancer Res. 2022 Mar 1;28(5):893-902. doi: 10.1158/1078-0432.CCR-21-3194. Clin Cancer Res. 2022. PMID: 34921023 Free PMC article. Clinical Trial.
Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 Study.
Saeki S, Hotta K, Sakata S, Oda N, Inoue K, Tamura T, Toyozawa R, Harada D, Tanaka K, Inoue K, Shioyama Y, Gemba K, Sasaki T, Bessho A, Kishimoto J, Katsui K, Kiura K, Sugio K. Saeki S, et al. Among authors: bessho a. Cureus. 2025 Jun 23;17(6):e86575. doi: 10.7759/cureus.86575. eCollection 2025 Jun. Cureus. 2025. PMID: 40704256 Free PMC article.
A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401.
Ninomiya K, Yokoyama T, Hotta K, Oze I, Katsui K, Hata T, Yoshioka H, Bessho A, Hosokawa S, Kuyama S, Kudo K, Kozuki T, Harada D, Yasugi M, Murakami T, Nakanishi M, Takigawa N, Maeda Y, Kiura K; Okayama Lung Cancer Study Group. Ninomiya K, et al. Among authors: bessho a. Support Care Cancer. 2021 Sep;29(9):5237-5244. doi: 10.1007/s00520-021-06092-1. Epub 2021 Mar 1. Support Care Cancer. 2021. PMID: 33649919 Clinical Trial.
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer.
Masuda T, Miura S, Sato Y, Tachihara M, Bessho A, Nakamura A, Miyawaki T, Yoshimine K, Mori M, Shiraishi H, Hamai K, Haratani K, Maeda S, Tabata E, Kitagawa C, Tanizaki J, Imai T, Nogami S, Yamamoto N, Nakagawa K, Hattori N. Masuda T, et al. Among authors: bessho a. Sci Rep. 2023 Nov 13;13(1):19729. doi: 10.1038/s41598-023-45337-3. Sci Rep. 2023. PMID: 37957228 Free PMC article.
Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study.
Makiguchi T, Tanaka H, Morikawa K, Hirata A, Itani H, Tanzawa S, Watanabe K, Yasuda H, Horiuchi K, Nakagawa H, Seki Y, Nakahara Y, Hayashi K, Takahashi N, Endo T, Bessho A, Okano T, Takeyama K, Kawase A, Endo M, Maekura T, Nemoto K, Takigawa N, Kishi K, Soejima K, Okuma Y, Togashi A, Matsutani N, Shinchi H, Ueda K, Seki N. Makiguchi T, et al. Among authors: bessho a. Cancer Treat Res Commun. 2025;44:100952. doi: 10.1016/j.ctarc.2025.100952. Epub 2025 May 31. Cancer Treat Res Commun. 2025. PMID: 40466414 Free article.
94 results